Exosome Facial: FDA Status, Evidence and Exosomes vs PRP

An exosome facial is almost always two things done together: a procedure that breaks the skin surface, and a product spread over that skin whose label says it contains exosomes. The procedure is usually microneedling, radiofrequency microneedling such as Morpheus8 or a resurfacing laser. The product is a serum, a gel or a powder mixed with liquid at the visit, sometimes followed by a cream you use at home.

That pairing is also how the research has been done. A 2026 scoping review of clinical studies found exosome products delivered by topical application, microneedling, fractional CO2 laser or injection. In a 2023 randomized trial, a commercial exosome solution was spread on half the face and then microneedled in at a depth of 1 mm. In a 2025 trial, exosome products went onto skin just treated with radiofrequency microneedling, followed by an exosome cream at home for 10 days.

Some providers go further and inject exosome products into the skin. That is a different treatment with a different risk profile, and the exosome case reports of lasting lumps and scarring cited in section 8 involve injection rather than surface application.

You will also see these treatments sold as regenerative aesthetics. That is not a regulatory category. The FDA's term is regenerative medicine products, and its consumer pages name exosomes alongside stem cells, fat-derived cells, umbilical cord blood, amniotic fluid and Wharton's jelly.

Exosomes are one kind of extracellular vesicle: a particle released from a cell, wrapped in a fatty double membrane, with no working nucleus, so it cannot copy itself. Through what they carry, these vesicles can change how other cells function, which is why researchers study them as signaling carriers and as possible therapies.

The word exosome has a narrow scientific meaning. The International Society for Extracellular Vesicles uses it for vesicles that start inside the cell's endosomal system, a subtype of small vesicles generally under 200 nanometers across. Its 2023 guidance discourages the word unless that origin can actually be shown, because without that proof a broad mix of vesicles is being studied, not exosomes specifically.

So when a skin product says exosomes, read it as a vesicle preparation of some kind rather than a single defined ingredient. The label word alone does not tell you the source, the amount or how the product was purified.

The vesicles themselves are not living cells, which is the main way an exosome product differs from a stem cell treatment. They are made by cells, but with no working nucleus they cannot grow or divide.

The vesicles in products sold for skin use come from several very different sources, and one label word covers all of them. Most clinical studies used vesicles from human mesenchymal stem cells, while other products use plant-derived vesicles or combine the two. The table sorts the sources that appear in the studies and FDA documents behind this guide.

Human-derived vesicles are collected from donor cells kept in culture. The questions that matter for them are the ones the FDA raises about regenerative medicine products generally: contamination with bacteria, viruses or mold during processing, and whether the material was tested for infectious diseases such as hepatitis and HIV. A label cannot answer either question. The manufacturer's documentation can.

Plant-derived vesicles, often called exosome-like nanovesicles, avoid a human donor but bring their own gap. A 2025 review of plant vesicles for sun-damaged skin found no unified standards for separating and extracting them, noted that related regulatory procedures are absent, and warned that different methods produce different yields and purities.

One product can contain more than one source. A post-treatment product in a 2025 facial trial combined human adipose stromal cell exosomes with rose plant stem cell exosomes, plus growth factors, peptides, amino acids and humectants. When you ask what a product is made from, ask for every source, not just the headline one.

No. The FDA has stated since December 6, 2019 that there are currently no FDA-approved exosome products, and its consumer alert on regenerative medicine products, last updated in April 2024, still says so. The FDA's list of licensed cellular and gene therapy products, updated September 17, 2026, contains no exosome product.

The 2019 notice followed multiple reports of serious adverse events in patients in Nebraska who had been treated with unapproved products marketed as containing exosomes, reports brought to the FDA by the Centers for Disease Control and Prevention among others. The notice does not describe facial treatments. Its point was broader: some clinics were telling patients these products fell outside the rules for drugs and biological products, and the FDA said that is simply untrue.

The FDA's position is that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products and need premarket review and approval. While such a product is still being studied, it may be given to people only under an Investigational New Drug application, known as an IND.

Two phrases patients hear deserve a direct answer. FDA registered is not approval: the FDA says that a firm registering with the agency and listing its product does not mean the product is legally marketed, and neither does a listing on clinicaltrials.gov. If a clinic says a product is investigational, the FDA tells patients to ask for the IND number and the FDA communication acknowledging it before treatment.

One distinction keeps this accurate. A product sold purely as a cosmetic, claiming only to improve appearance, does not need FDA approval before it is sold. The next section explains where that line falls and why many exosome products cross it.

Under federal law a product's category depends on what it is intended to do, so an exosome product sold to repair, regenerate or treat skin is legally a drug, and one made from human cells is also a biological product. Calling it a cosmetic does not settle the question.

The Federal Food, Drug, and Cosmetic Act defines cosmetics as products applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance. It defines drugs to include products intended to treat or prevent disease or to affect the structure or any function of the body. Cosmetics, other than color additives, need no FDA approval before they go on sale. Drugs generally do.

Intended use is judged from the claims made in labeling, advertising, websites and other promotion. The FDA's own examples of claims that make a product a drug include restoring hair growth, changing the skin's production of melanin and claims that a product will regenerate cells. Regeneration and repair were central to how the products in the two warning letters below were promoted.

In May 2025 the FDA warned a Texas company selling umbilical cord stem cell exosome gels. The letter quotes the company's claims that its exosomes may influence collagen organization and fibroblast activity, key factors in skin repair, and that exosome therapy reduces wrinkles, fine lines and sagging skin. The FDA concluded the products were unapproved new drugs and unlicensed biological products. A website disclaimer that the products were for research and investigational purposes did not help, because no IND was in effect.

In September 2023 the FDA warned Kimera Labs, a Florida manufacturer of the exosome products XoGlo and XoGlo Pro, which had been distributed to practitioners and medical facilities across the United States. The company told inspectors its exosome products were for cosmetic use. The FDA pointed to labeling that listed an indication of treating skin damage after cosmetic or other facial injury by heat, light, physical or chemical damage, and treated the products as drugs and biological products.

The same letter described manufacturing problems. The aseptic processes had not been validated for products that claimed to be sterile, there was no documented investigation of a positive sterility result for one XoGlo Pro lot whose vials had all been distributed, and culture media components labeled for research use only went into products used in people. Across the company's products, the deviations involved more than 37,000 vials made between April 2020 and June 2022. In June 2026 the FDA closed out the letter after the company said it had stopped making and selling the products, and noted that a 2024 follow-up inspection found no evidence it was still doing so.

None of this means every exosome serum is illegal or contaminated. It means the paperwork behind the vial matters, and the patient is usually the last person to see it. The same supply chain problem is why the guide to counterfeit and grey-market injectables tells you to ask to see the packaging before anything touches your skin.

Microneedling makes many small puncture holes into the living layers of the skin, so a product applied during or right after it can reach the dermis instead of sitting on the surface. That is the selling point of the pairing, and it is also the reason for caution.

Dermatologists at the University of Utah described three women who developed facial granulomas, firm inflammatory lumps, after microneedling for skin rejuvenation; two had the same branded vitamin C serum microneedled into the skin. The authors concluded that applying topical products before microneedling can introduce immunogenic particles into the dermis and make local or body-wide hypersensitivity reactions more likely. That report did not involve exosomes. It shows why a product being tolerated on intact skin does not tell you how it behaves inside it.

The FDA's microneedling page makes the same point in regulatory terms. It states that microneedling devices are not approved for delivering cosmetics, topical medications, drugs or blood products such as PRP into the skin, and that the risks of combining microneedling devices with other products are not known. It also notes that microneedling may be considered a medical procedure, not a cosmetic one, for example when it is intended to change the structure or function of tissue.

The controlled exosome trials described in section 7 reported reassuring short-term safety. But they tested specific products under study conditions. Whether the vial in your clinic is the same product, sterile and within its expiration date is a separate question, and the Kimera findings show why it is worth asking.

If the base procedure is radiofrequency microneedling, there is an added layer. In October 2025 the FDA reported serious complications with certain uses of radiofrequency microneedling devices, including burns, scarring, fat loss, disfigurement and nerve damage, and stated that radiofrequency microneedling is a medical procedure, not a cosmetic treatment.

The evidence is early. Controlled trials are few, small and short, and the systematic reviews agree that short-term results look promising but that small samples, short follow-up and risk of bias limit what can be concluded.

The closest match to the med spa version is a 2023 randomized split-face trial from Korea. Twenty-eight people had three microneedling sessions three weeks apart, with a commercial adipose stem cell exosome solution on one side of the face and saline on the other, and were followed for six weeks after the last session. The exosome side scored better on a global improvement scale and on device measurements of wrinkles, elasticity, hydration and pigmentation, and no serious adverse events were seen. The authors, who declared no conflicts of interest, noted that all participants were of one ethnicity, the group was small and follow-up was short.

A 2025 US trial compared exosome products with PRP after radiofrequency microneedling in 15 people, exosomes on one side of the face and PRP on the other. Both sides improved. The authors reported that overall appearance was not significantly different between the sides at six months, with slightly more improvement on the exosome side for wrinkling, redness and texture. They also state that statistics were not run on the clinical assessments because the sample was so small, the sides were not randomized, and the study was supported in part by a research grant from the company that makes the exosome products tested.

Clinics often say exosomes shorten recovery. The most direct test is a 2020 randomized, double-blind split-face trial from Korea: 25 people with acne scars had three fractional CO2 laser sessions, with an exosome gel on one side of the face and a control gel on the other. Redness after treatment was milder on the exosome side, and downtime averaged 4.1 days on that side against 4.3 days on the control side. The exosome maker produced and supplied both gels. That is a measurable difference, but it is a few hours after a laser, not a way to skip recovery.

The reviews say the same thing at larger scale. A 2025 systematic review in Stem Cell Research and Therapy covered 19 studies with 624 patients using vesicles or conditioned media for skin rejuvenation and lightening. It rated 5 studies at low risk of bias, 11 with some concerns and 3 at high risk, found no serious adverse effects, and said long-term safety, particularly with repeated use, remains unclear. A 2026 scoping review in the Journal of Drugs in Dermatology found 17 clinical studies published from 2020 to 2025, reported improvements in 76 percent of them, and named small samples, short follow-up, non-randomized single-arm designs and potential conflicts of interest as limits.

Two cautions help when you read any claim built on these studies. First, the controlled trials test an add-on: a procedure plus an exosome product against the same procedure plus saline or PRP. They do not test exosomes on their own. Second, results from one manufacturer's product do not carry over to another, because the word exosome covers very different preparations.

Duration is the biggest gap. The two controlled facial trials above followed people for six weeks and six months after treatment, so no published figure tells you how long any improvement lasts or how often it would need repeating. Clinics often sell exosome facials as a series. The only schedule tested in a controlled microneedling trial was three sessions three weeks apart, so a longer series is the clinic's protocol rather than something the studies compared.

The risks come from three places: the procedure that opens the skin, the quality of a product no regulator has approved, and the step some providers take of injecting a product made for the surface. Microneedling itself carries the risks the FDA lists for authorized devices. Common ones are dryness, rough skin, tightness, redness, itching, peeling, discomfort, burning, bruising, bleeding and crusting. Less common ones include pigment changes, reactivation of cold sores, swollen lymph nodes, infection, and stinging or itching when cosmetic products are applied.

Product quality is the risk you cannot see. Among the safety concerns the FDA lists for products illegally marketed as regenerative medicine therapies are bacterial infections, including life-threatening blood infections, contamination with bacteria, viruses or mold during processing, products not tested for infectious diseases such as hepatitis and HIV, and unwanted inflammatory or immune reactions. The sterility findings in the Kimera letter are a concrete example of how that can happen before a product ever reaches a clinic.

Injection is where the most serious exosome case reports sit. A 2025 case series from Korea described four women who had exosome-containing products injected into the skin in a nonclinical setting and developed persistent redness, nodules, granulomatous inflammation and scarring.

Treatment with steroids, lasers and surgical removal left all four with incomplete resolution and residual scars. The author notes these cosmetic products are approved for topical use and that injecting them is off-label and unregulated in many countries, including South Korea. The 2026 scoping review likewise lists granulomas, necrosis and allergic reactions after injection among reported adverse events.

Keep it in proportion. In the two controlled trials of topical exosome products after needling, no serious adverse events were reported, and the 2025 trial described only redness and swelling that cleared within a week. The serious harms in the sources behind this guide cluster around unapproved products, unclear sourcing and injection outside medical settings, which is why the questions in the next section matter more than the brand name. The guide to red flags at a medical spa covers the wider warning signs.

If something goes wrong, see a licensed clinician promptly. You can also report it to the FDA through MedWatch, the program the agency asks patients and health care professionals to use for adverse events involving exosome products.

Ask for the product by name and for the paperwork behind it. A clinic using an exosome product responsibly can answer each question below without hesitation, and the broader list of questions to ask at a med spa consultation covers the rest of the visit.

What is the exact product name, and who manufactures it? Write both down. A generic answer such as our exosome serum is not an answer, because the studies tested specific products and results do not transfer between them.

What are the vesicles made from? Human adipose, umbilical cord or other stem cells, conditioned media, plants, or a mix. If any of it is human-derived, ask what donor screening, infectious disease testing and sterility testing the manufacturer documents.

Will it be applied to the surface or injected? If a provider proposes injecting an exosome product, ask why, what the product's own labeling says about injection, and how they would manage a nodule if one formed. The published case reports of lasting lumps and scars involve injection.

What is its FDA status, in the provider's own words? If the answer is FDA approved, ask to see the approval, because the FDA says none exists. If the answer is FDA registered, the FDA says registration does not mean a product is legally marketed. If the answer is investigational, ask for the IND number and the FDA acknowledgment, as the FDA advises.

Is it sterile, sealed and single-use? Ask to see the vial or packet, the lot number and the expiration date, and ask that it be opened in front of you. For the needling step, the FDA says to ask whether a new microneedle cartridge is used for each patient and each session, and calls reuse unsafe. The guide to med spa sanitation and sterilization standards explains what else to look for.

Who performs the procedure, and who supervises it? The FDA advises choosing a provider trained to perform microneedling and asking about that training and experience. Then ask what the base procedure costs without the add-on, so you can see what the exosome step itself is costing you.

If your goal is texture, fine lines or acne scarring, the base procedures have firmer support than the exosome add-on. Microneedling devices have FDA authorization for specific uses, and adding PRP to microneedling has a larger body of controlled studies for acne scars, although PRP has regulatory gaps of its own.

Microneedling alone is the procedure underneath every exosome facial. The FDA has authorized microneedling devices to improve the appearance of facial acne scars, facial wrinkles and abdominal scars in people 22 and older, which means the agency reviewed data supporting a reasonable assurance of safety and effectiveness for those uses. If you are weighing it against a peel, microneedling vs chemical peel compares the two.

PRP, platelet-rich plasma, is prepared from your own blood, drawn at the visit and spun in a centrifuge to concentrate the platelets, so there is no donor material. A 2022 meta-analysis of 4 randomized and 10 non-randomized split-face studies with 472 patients found that microneedling with PRP gave better acne scar improvement and higher patient satisfaction than microneedling alone, with no significant difference in severe redness or swelling. The regulatory picture is less tidy: PRP preparation systems reach the market through FDA 510(k) clearance, nearly all for mixing with bone graft material, so facial use is off-label, and the FDA says microneedling devices are not approved for delivering PRP into the skin. The PRP vs microneedling guide and the PRP facial overview cover what the combination involves.

If laser resurfacing is also on your list, microneedling vs laser resurfacing sets the two side by side. Whichever route you choose, the comparison below is the one to bring to a consultation.